Keyword: Farxiga

After AstraZeneca released overall CV outcomes results for Farxiga, the company has dug further into the data and presented two subanalyses on Monday.

With outcomes data showing Farxiga lowers hospitalizations for heart failure or CV deaths against placebo, AZ plans to file for a new FDA label.

With data showing Farxiga can reduce hospitalizations for heart failure or CV deaths against placebo, AZ plans to seek a label update.

The FDA has raised red flags about a potentially serious flesh-eating disease in patients taking SGLT2 inhibitors.

J&J’s Invokana will have to wait longer for the FDA to decide on a key label expansion, but it's still got good news to celebrate.

At ADA, an AstraZeneca executive said he's "very optimistic" about the company's cardiovascular outcomes study for Farxiga.

In a new post-hoc analysis of Jardiance's CV outcomes test, investigators found that the drug reduced kidney disease progression.

Invokana carries a warning for amputation risks, but an analysis found the drug lowered heart failure hospitalizations without increasing those risks.

AstraZeneca may be the first pharma to encourage use of the “F-word.” Although in this case, AZ is talking about its diabetes drug Farxiga.

When it comes to real-world heart benefits, SGLT2 diabetes drugs continue to impress—this time with reduced risks of heart attack and stroke.